影响TGF-β1信号传递 甲福林对血糖控制的作用
Quan Pan1, Weiqi Ai1, Shaodong Guo1
1Department of Nutrition, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX 77843, USA.
International journal of molecular sciences
|February 24, 2024
概括
转化生长因子β1 (TGF-β1) 损害了甲福林的作用.
科学领域:
- 代谢过程中的代谢.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 高血糖是2型糖尿病 (T2D) 的特征.
- 甲福明是一种第一线T2D治疗方法,可以抑制肝脏葡萄糖 (HGP) 的产生.
- 随着时间的推移,大多数T2D患者会产生对甲胺的耐药性,T2D肝脏和血清中观察到TGF-β1的升高.
研究的目的:
- 研究转化生长因子β1 (TGF-β1) 在2型糖尿病 (T2D) 中对美特福林耐药性的作用.
- 探索TGF-β1信号传导作为一种潜在的治疗点,以提高甲福林的疗效.
主要方法:
- 用TGF-β1和甲福林治疗的细胞和小鼠.
- 使用高脂肪饮食 (HFD) 诱导的肥胖小鼠和肝脏胰岛素受体基质1 (IRS1) 和IRS2双淘汰赛 (DKO) 小鼠模型.
- 评估了甲福明对血糖控制和肝脏葡萄糖 (HGP) 生产的影响.
- 研究了肝脏TGF-β1缺乏和TGF-β1信号阻塞 (使用LY2157299) 对甲胺作用的影响.
主要成果:
- 通过抑制AMPK酸化,TGF-β1治疗会降低甲胺抑制HGP的能力.
- 肝脏TGF-β1缺乏改善了在肥胖小鼠中的甲福明的血糖控制功效.
- 在肝脏胰岛素耐药小鼠中,甲福尔明的疗效受损,但通过删除肝脏TGF-β1或Foxo1.1来改善.
- 阻断TGF-β1信号增强了小鼠对甲福林的敏感性.
结论:
- 肝脏TGF-β1信号对二型糖尿病中甲福林降血糖效应产生负面影响.
- 抑制TGF-β1信号显示出作为一种组合疗法的潜力,以提高T2D治疗中甲福林的有效性.
更多相关视频
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
201
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
201
Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
175
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Glucagon-like Receptor Agonists
322
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
322
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K


